Comparative Pharmacology
Head-to-head clinical analysis: NEORAL versus SIROLIMUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEORAL versus SIROLIMUS.
NEORAL vs SIROLIMUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclosporine, the active ingredient in Neoral, is a calcineurin inhibitor. It binds to cyclophilin, forming a complex that inhibits calcineurin, thereby preventing dephosphorylation and nuclear translocation of NF-AT (nuclear factor of activated T-cells). This inhibits transcription of interleukin-2 and other cytokines, reducing T-cell activation and proliferation.
Sirolimus is an immunosuppressant that forms a complex with FKBP12, which inhibits the mechanistic target of rapamycin (mTOR), a key regulator of cell cycle progression and proliferation. This inhibition blocks signal transduction from cytokine and growth factor receptors, thereby suppressing T-cell activation and proliferation.
Initial dose 10-15 mg/kg/day orally divided q12h, then taper by 5% weekly to maintenance of 3-5 mg/kg/day divided q12h. For psoriasis: 2.5 mg/kg/day orally divided q12h. For rheumatoid arthritis: 2.5-5 mg/kg/day orally divided q12h. Administer consistently with or without food.
Loading dose of 6 mg orally on day 1, followed by 2 mg orally once daily; or 3 mg orally on day 1, followed by 1 mg orally once daily. Maintenance dosing adjusted to achieve trough concentrations of 4-20 ng/mL. For de novo renal transplant recipients: 6 mg loading dose then 2 mg/day.
Clinical Note
moderateSirolimus + Digoxin
"Sirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemsirolimus + Digoxin
"Temsirolimus may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateSirolimus + Digitoxin
"Sirolimus may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemsirolimus + Digitoxin
"Temsirolimus may decrease the cardiotoxic activities of Digitoxin."
None Documented
None Documented
Terminal elimination half-life: 8.4 hours (range 6–24 hours) in healthy volunteers; prolonged in hepatic impairment (up to 20 hours).
Terminal half-life approximately 57-63 hours in adults, allowing once-daily dosing; longer in hepatic impairment.
Primarily biliary/fecal (94%): 94% of dose eliminated in feces via bile, 6% in urine (0.1% unchanged). Minimal renal elimination of parent drug.
Primarily fecal (91%) with minimal renal excretion (2.2% as metabolites).
Category C
Category D/X
Immunosuppressant
Immunosuppressant